1. Field of the Invention
The present disclosure generally relates to rechargeable battery systems. More particularly, the present disclosure relates to a method for estimating remaining battery capacity using an algorithm based on battery terminal voltage.
2. Description of the Related Art
In recent years there has been an explosion in the popularity and types of portable electronic devices. Such devices include communication and entertainment devices, such as cell phones, PDA's, portable music and video players and the like, as well as electronic devices that are implantable into a human or animal body, such as pacemakers, implantable drug delivery systems and nerve stimulation devices. These and other types of portable electronic devices generally rely upon electrochemical storage batteries as a power source. Many of these devices use rechargeable batteries, while others use conventional single-use batteries. In either case, however, it can be desirable to have an accurate estimate of remaining battery capacity or battery life in order to know when to recharge or replace the batteries. This is particularly true in the case of implantable electronic devices, where the health of the user may depend upon proper functioning of the device, and the device is not easily accessible, since replacing a battery requires an invasive surgical procedure.
There are various known methods for estimating remaining battery life in electronic devices that are currently used. For example, methods that have been adopted to predict or estimate remaining battery life include the remaining capacity (mAh) method, direct energy computation (J), and the coulomb counter (Amps/s) method. Unfortunately, many of these methods rely upon some significant and sometimes inaccurate assumptions, can be moderately to highly complex to implement, and the accuracy of these methods varies widely. Ironically, some battery life estimation methods that are currently used are computationally intensive, such that they impose a substantial strain on battery life in the course of computing battery life and reduce overall system efficiency.
The present disclosure is directed to overcoming, or at least reducing the effects, of one or more of the issues set forth above.
It has been recognized that it would be advantageous to develop a simple and robust method for estimating remaining battery capacity in an electronic device.
It has also been recognized that it would be advantageous to develop a method for estimating remaining battery capacity in an electronic device that uses only minimal power from the electronic device itself
In accordance with one aspect thereof, the present disclosure provides a method for managing a battery powering an implantable medical device (IMB) comprising taking a plurality of regular, periodic terminal voltage readings of the battery in the IMD and estimating future battery performance characteristics based upon a linear extrapolation from the plurality of voltage readings. The performance characteristics may include at least one of time to depletion of the battery and time to end of service of the battery.
The method may further comprise obtaining a baseline curve of voltage depletion over time for the battery in the IMD under selected operating parameters and making a first estimate of future battery performance characteristics based upon a linear extrapolation from the plurality of voltage readings and an initial point of the baseline curve. The method may further comprise modifying the baseline curve based upon a change of the operating parameters of the IMD. The method may further comprise wirelessly transmitting data representing the detected terminal voltage of the battery from the IMD to a remote computing device. The IMD may be an implantable pulse generator for vagus nerve stimulation.
The IMD may take the plurality of regular, periodic terminal voltage readings and a remote computing device may estimate the future battery performance characteristics. The remote computing device may be a PDA, smartphone, laptop computer, or a special purpose portable computing device. The method may further comprise providing to a user of the IMD an indication of the future battery performance characteristics. The indication may be an indicator light, an alphanumeric display, an iconic indicator, or an audible indicator.
In accordance with yet another aspect thereof, the present disclosure provides a method of estimating a life of a battery in an implantable medical device (IMD). The method comprising obtaining a baseline curve of voltage depletion over time for the battery in the IMD under selected operating parameters, taking a first reading and subsequent readings of battery terminal voltage at regular intervals, making a first battery life estimate based upon a linear extrapolation from the first voltage reading and the baseline curve, and making subsequent battery life estimates based upon a linear extrapolation of the subsequent voltage readings.
The battery life estimate may include time to depletion of the battery and/or time to end of service of the battery. The regular interval for taking readings of the battery terminal voltage may be about once per day. The method may further comprise providing to a user an indication of the first or subsequent battery life estimates using an indicator. The indicator may be an indicator light, an alphanumeric display, an iconic, indicator, audible indicator, or equivalent device. The method may further comprise wirelessly transmitting data representing the voltage readings from the IMD to a remote computing device, with the IMD taking the first and subsequent reading of battery terminal voltage and the remote computing device performing the first and subsequent battery life estimates.
In accordance with yet another aspect thereof, the present disclosure provides an implantable system comprising an implantable device having a microprocessor, system memory, a battery, and a battery circuit capable of measuring battery terminal voltage. The system comprises an external computing device having a microprocessor and system memory and a computer program product. The computer program product being stored in the system memory of the implantable device or the external computing device. The computer program product comprising machine-readable instructions for periodically measuring terminal voltage of the battery and estimating a life of the battery based upon a linear extrapolation from the plurality of the periodic voltage measurements.
The system memory may include data representing a baseline curve of voltage depletion over time for the battery in the implantable device under selected operating parameters and the computer program product may include instructions for making a first estimate of the life of the battery based upon the baseline curve and first of the periodic voltage measurements. The implantable device may further comprise a wireless transmitter and programming instructions for periodically measuring terminal voltage of the battery and transmitting data representative thereof to the external device.
These and other embodiments of the present application will be discussed more fully in the description. The features, functions, and advantages can be achieved independently in various embodiments of the claimed invention, or may be combined in yet other embodiments.
While the disclosure is susceptible to various modifications and alternative forms, specific embodiments have been shown by way of example in the drawings and will be described in detail herein. However, it should be understood that the disclosure is not intended to be limited to the particular forms disclosed. Rather, the intention is to cover all modifications, equivalents and alternatives falling within the spirit and scope as defined by the appended claims.
Illustrative embodiments are described below as they might be employed in a method for estimating battery capacity. In the interest of clarity, not all features of an actual implementation are described in this specification. It will of course be appreciated that in the development of any such actual embodiment, numerous implementation-specific decisions must be made to achieve the developers' specific goals, such as compliance with system-related and business-related constraints, which will vary from one implementation to another. Moreover, it will be appreciated that such a development effort might be complex and time-consuming, but would nevertheless be a routine undertaking for those of ordinary skill in the art having the benefit of this disclosure.
Further aspects and advantages of the various embodiments will become apparent from consideration of the following description and drawings. These embodiments are described in sufficient detail to enable those skilled in the art to practice the invention, and it is to be understood that modifications to the various disclosed embodiments may be made, and other embodiments may be utilized, without departing from the spirit and scope of the present invention. The following detailed description is, therefore, not to be taken in a limiting sense.
As used herein, the term “implantable” means a device that can be completely implanted into a human or animal body, with no portions of the apparatus extending outside the body after implantation.
As used herein, the terms “implantable device” and “implantable medical device” or “IMD” mean any type of electrical device that is implantable into a human or animal body, and is configured to monitor or affect a function of the body. Examples of implantable medical devices include cardiac pacemakers, nerve stimulation devices, and implantable drug delivery devices.
As noted above, there are a variety of battery powered devices in which it is desirable to have an accurate estimate of remaining battery power. In addition to communication and entertainment devices, this includes implantable devices that can be used for monitoring and affecting physiological or biological function of a human or animal body. Such devices include cardiac pacemakers, implantable drug delivery systems and nerve stimulation devices. Among the latter are implantable devices for vagus nerve stimulation (VNS). VNS was approved by the FDA in 1998 as an adjunctive therapy for epilepsy with partial onset seizures. VNS is achieved through an implanted pulse generator that delivers a bipolar, biphasic pulse to the vagus nerve. The implant procedure is very similar to the implantation of a pacemaker. The generator is implanted subcutaneously, typically in the upper left pectoral region. An electric lead is connected between the pulse generator and one or more electrodes that are attached to the vagus nerve. While the following description presents a system and method for estimating battery life in the context of an implantable vagus nerve stimulation system, this application is only exemplary. It is to be understood that the system and method disclosed herein can be applied to a wide variety of battery-powered electronic devices, and is not limited to the particular exemplary application in which it is shown and described.
Shown in
The pulse generator 14 can be a multi-programmable device, which allows a physician to set various parameters of operation of the device. The programmable parameters can include signal amplitude (e.g., 0-3.5 mA), frequency (e.g., 1-30 Hz), pulse width (e.g., 130-1000 μs), signal ON time (e.g., 7-60 sec) and signal OFF time (e.g., 0.2-180 min). It is to be appreciated that these pulse parameters are only exemplary, and that other parameters can also be used. The pulses can be delivered at the specified amplitude and frequency over the course of the ON time, and then during the OFF time, no stimulation takes place. This type of device typically does not stimulate continuously because it has been found that the antiepileptic effect tends to last much longer than the actual time of stimulation. In one embodiment, pulse settings can be 2 mA, at 15 Hz frequency, 250 μs pulse width, with a 30 sec ON time, and 5 min OFF time. The variability in parameters allows the physician to adjust for greater efficacy or less severe side effects, depending on the patient.
As shown in
A more specific schematic diagram of the internal components of an embodiment of an implantable pulse generator device, indicated generally at 300, is shown in
Also operatively connected to the logic and control unit 302 are the crystal oscillator 308 and the voltage regulator 304. The crystal oscillator 308 provides an accurate time signal for the logic and control unit 302. The voltage regulator 304 controls power input from the battery 314 to the logic and control unit. The pulse generator can also include a reed switch 316 that allows selective connection of the logic and control unit 302 or output unit 306 to ground 317. This allows the pulse generator device 300 to operate in a secondary magnet mode, delivering a pre-programmed burst of stimulation when activated by an external magnet (e.g., a permanent magnet worn on the patient's wrist and swiped over switch 316 to activate the secondary mode of operation). While the elements shown in
While a GPS transceiver (26 in
The smart phone 52 and wristwatch device 54 are shown in
Performing various computational operations and/or having various hardware components included within a device other than the pulse generation device 14 can be desirable for power conservation. For example, power-hungry microprocessing tasks and analysis can be transferred to the external device, rather than being performed by the microprocessor 28 of the pulse generation device 14, with the results of those microprocessing tasks transmitted back to the implanted device 14. This can conserve power for the implanted device 14. Similarly, having an external GPS transceiver and associated microprocessor can also reduce power demands on the implanted pulse generator 14. A GPS transceiver that is in substantially constant communication with a GPS satellite system and a microprocessor that analyzes the positional information can use significant power, which is at a premium with implanted devices.
One microprocessing task that can be performed by an external device in communication with a battery powered device is computation of battery life or estimation of time to depletion or end of service of a battery. As noted above, it is desirable to have an accurate estimate of remaining battery power and battery life for a battery-powered electronic device. This is of particular interest for implanted devices, since the health of the user may depend upon the device, and direct access to the battery generally requires a surgical procedure. Thus, for example, the microprocessor associated with a smart phone 52 or wristwatch device 54 or some other external device can be programmed to receive battery data measurements (e.g. open circuit voltage), transmitted from the pulse generator 14, and perform the analysis to estimate remaining battery life. The external device can then transmit battery information, operational commands or other information to the pulse generation device 14 or some other device.
Advantageously, a method has been developed for more accurately estimating battery capacity and time to battery depletion in an electronic device, such as an implanted pulse generator device like that shown in
The method disclosed herein, based on the battery's voltage depletion rate (VDR) provides a simple implementation, and its estimation gets more accurate over time, especially in the last 25% of the battery's useable life threshold. The method utilizes samples of battery voltage measurement and a lookup table of various voltage load curves. An appropriate load curve can be used for initial base line estimate only, after which direct voltage measurements are used to provide a linear extrapolation to battery depletion. As time passes, the battery voltage measurement determines the VDR of the battery over a given time period, with greater and greater accuracy.
Provided in
The load curves 600a-e shown in
A second approach to selecting or establishing a VDR load curve is to extract two boundary load curves, one for the minimum possible load and another for the maximum possible load (the best case and the worst case) that the system is expected ever to experience. This approach is illustrated in the graph of
Referring back to
Several points of interest are shown on the top line of the graph of
After the IFI point has been crossed, the next point of interest in this embodiment is the near end of service (NEOS) point 608. In one embodiment, this point can represent a voltage of 2.41 volt, with about 5% of remaining battery capacity. Reaching the NEOS point can be viewed as indicating that the battery should be replaced as soon as possible. Again, an indication of NEOS can be provided to a user on an external device. Upon reaching the NEOS point, or at some voltage level thereafter, the implanted device can be programmed to discontinue full functioning, and revert to an energy saving mode, where only essential operations are undertaken to maintain memory, transmit data, or receive data, etc.
The next point of interest is the end of service (EOS) point 610, indicating that the battery's useful life is over (0% remaining capacity). A suitable EOS indication can be provided to an external device. In one embodiment the EOS point 610 represents a voltage of about 2.0 volt. At this point, there is still some charge left in the battery, but the voltage level has become too low to maintain even basic functioning of the implanted device.
Referring back to
Given potential errors in the initial assumptions for the voltage depletion curve, it is possible that the initial voltage depletion estimate may have some error. For example, as can be seen in
Only a few actual voltage measurements are needed to establish a more reliable VDR curve. After each analysis step (step 408), the VDR load curve can be revised (step 410) based on the actual voltage measurements. Based on the linear extrapolation in view of the new voltage measurements, the time to IFI, NEOS, EOS and time to recharge can be estimated (step 412). This new battery life estimate can be provided as output to a user (step 414) and transmitted back to the implanted device, such as an IPG (step 418) if desired. The system can then also record the new boundary and curve fit data (step 420). Output and indications to a user can be provided in a variety of ways. For example, an external device can have an alphanumeric display (e.g. an LCD screen) that provides specific words or indications to a user, including icons indicating different battery conditions. Alternatively, an external device can have indicator lights or audio alerts that provide battery life indications. An audible alert can also be provided by an implanted device itself. Other options can also be used.
The process of using multiple voltage measurements to produce a linear fit is illustrated in
There are various boundary points that can be used for the linear fit approximation. In one embodiment, these boundary points can correspond to the IFI, NEOS and EOS points shown in
By using the disclosed linear fit methods, the time required for the battery's terminal voltage to reach a given depleted value can be more accurately predicted. Some aspects of these methods can require care and consideration during application. For example, it has been found that the accuracy of the battery life estimate can decline if the computation of the estimate is done within an hour of the effective change of the load and/or the load parameters. That is, if a physician changes operating parameters of the implanted device (e.g. through wireless transmission of new operating instructions to the implanted device), such as duty cycle, stimulation current, etc., a voltage measurement taken shortly after that sort of change can produce an inaccurate battery life estimate. However, such errors will gradually work themselves out with regular repeated voltage measurements in the subsequent days or weeks. In some embodiments, the system can be programmed to select or establish a new VDR curve as a starting point whenever new operational parameters are initiated. That is, each time operational parameters are changed for the implanted device, the system can revert to step 400 in the process outlined in
Similarly, if the implanted device is provided with a rechargeable battery, a new VDR curve can be selected or established each time the battery is recharged. A rechargeable battery may have a characteristic VDR curve, which can be analyzed using the methods disclosed herein.
As noted above, the method outlined in
The method disclosed herein provides a simple and accurate battery useable time estimation. The accuracy of the time estimation increases over time for a given operating load or operational regime. No additional hardware is required to implement this method. Advantageously, this method allows battery energy to be used to the greatest extent possible, providing longer operating time or time between surgical operations to replace or service in implanted device. This method is accurate and independent of battery capacity, operating environment, load behavior, and dynamic and or static loads, etc. The method is independent because it does not need as many inputs as other battery estimation methods and adapts to changes during operation of the device. That is, if manufacturing variations or material flaws, or an intentional change in operating parameters, cause a given implanted device to consume more power than expected, this additional power demand will naturally change the voltage depletion rate, which will be reflected in the actual voltage measurements. Consequently, the system will automatically compensate for changes in electrical function of the device.
Although various embodiments have been shown and described, the invention is not so limited and will be understood to include all such modifications and variations as would be apparent to one skilled in the art. For example, equivalent elements may be substituted for those specifically shown and described, certain features may be used independently of other features, and the number and configuration of various vehicle components described above may be altered, all without departing from the spirit or scope of the invention as defined in the appended claims.
Such adaptations and modifications should and are intended to be comprehended within the meaning and range of equivalents of the disclosed exemplary embodiments. It is to be understood that the phraseology of terminology employed herein is for the purpose of description and not of limitation. Accordingly, the foregoing description of the exemplary embodiments of the invention, as set forth above, are intended to be illustrative, not limiting. Various changes, modifications, and/or adaptations may be made without departing from the spirit and scope of this invention.
Number | Name | Date | Kind |
---|---|---|---|
3796221 | Hagfors | Mar 1974 | A |
4324251 | Mann | Apr 1982 | A |
4488555 | Imran | Dec 1984 | A |
4556061 | Barreras | Dec 1985 | A |
4686990 | Moberg | Aug 1987 | A |
4702254 | Zabara | Oct 1987 | A |
4715381 | Moberg | Dec 1987 | A |
4850356 | Heath | Jul 1989 | A |
4867164 | Zabara | Sep 1989 | A |
4899750 | Ekwall | Feb 1990 | A |
4964407 | Baker et al. | Oct 1990 | A |
5025807 | Zabara | Jun 1991 | A |
5127404 | Wyborny et al. | Jul 1992 | A |
5137020 | Wayne et al. | Aug 1992 | A |
5137021 | Wayne et al. | Aug 1992 | A |
5146920 | Yuuchi et al. | Sep 1992 | A |
5154172 | Terry, Jr. et al. | Oct 1992 | A |
5179950 | Stanislaw | Jan 1993 | A |
5188104 | Wernicke et al. | Feb 1993 | A |
5193538 | Ekwall | Mar 1993 | A |
5201808 | Steinhaus et al. | Apr 1993 | A |
5201865 | Kuehn | Apr 1993 | A |
5215086 | Terry, Jr. et al. | Jun 1993 | A |
5222494 | Baker, Jr. | Jun 1993 | A |
5231988 | Wernicke et al. | Aug 1993 | A |
5263480 | Wernicke et al. | Nov 1993 | A |
5269303 | Wernicke et al. | Dec 1993 | A |
5299569 | Wernicke et al. | Apr 1994 | A |
5330515 | Rutecki et al. | Jul 1994 | A |
5335657 | Terry, Jr. et al. | Aug 1994 | A |
5344431 | Merritt et al. | Sep 1994 | A |
5352968 | Reni et al. | Oct 1994 | A |
5372607 | Stone et al. | Dec 1994 | A |
5391193 | Thompson | Feb 1995 | A |
5431692 | Hansen et al. | Jul 1995 | A |
5458624 | Renirie et al. | Oct 1995 | A |
5496353 | Grandjean et al. | Mar 1996 | A |
5507786 | Morgan et al. | Apr 1996 | A |
5522865 | Schulman et al. | Jun 1996 | A |
5534018 | Wahlstrand et al. | Jul 1996 | A |
5540730 | Terry, Jr. et al. | Jul 1996 | A |
5540734 | Zabara | Jul 1996 | A |
5549646 | Katz et al. | Aug 1996 | A |
5571150 | Wernicke et al. | Nov 1996 | A |
5620474 | Koopman | Apr 1997 | A |
5703469 | Kinoshita | Dec 1997 | A |
5707400 | Terry, Jr. et al. | Jan 1998 | A |
5713936 | Staub | Feb 1998 | A |
5741307 | Kroll | Apr 1998 | A |
5741311 | McVenes et al. | Apr 1998 | A |
5744931 | Arai et al. | Apr 1998 | A |
5755742 | Schuelke et al. | May 1998 | A |
5769873 | Zadeh | Jun 1998 | A |
5814088 | Paul et al. | Sep 1998 | A |
5876425 | Gord et al. | Mar 1999 | A |
5891179 | Er et al. | Apr 1999 | A |
5897577 | Cinibis et al. | Apr 1999 | A |
5925068 | Kroll | Jul 1999 | A |
5928272 | Adkins et al. | Jul 1999 | A |
6016448 | Busacker et al. | Jan 2000 | A |
6073050 | Griffith | Jun 2000 | A |
6108579 | Snell et al. | Aug 2000 | A |
6148235 | Kuiper | Nov 2000 | A |
6167309 | Lyden | Dec 2000 | A |
6181969 | Gord | Jan 2001 | B1 |
6185461 | Er | Feb 2001 | B1 |
6212431 | Hahn et al. | Apr 2001 | B1 |
6317633 | Jorgenson et al. | Nov 2001 | B1 |
6341236 | Osorio et al. | Jan 2002 | B1 |
6400988 | Gurewitsch | Jun 2002 | B1 |
6445951 | Mouchawar | Sep 2002 | B1 |
6453198 | Torgerson et al. | Sep 2002 | B1 |
6473644 | Terry, Jr. et al. | Oct 2002 | B1 |
6490484 | Dooley et al. | Dec 2002 | B2 |
6490486 | Bradley | Dec 2002 | B1 |
6553263 | Meadows et al. | Apr 2003 | B1 |
6587719 | Barrett et al. | Jul 2003 | B1 |
6587727 | Osorio et al. | Jul 2003 | B2 |
6609025 | Barrett et al. | Aug 2003 | B2 |
6620186 | Saphon et al. | Sep 2003 | B2 |
6622038 | Barrett et al. | Sep 2003 | B2 |
6622041 | Terry, Jr. et al. | Sep 2003 | B2 |
6622047 | Barrett et al. | Sep 2003 | B2 |
6631293 | Lyden | Oct 2003 | B2 |
6648823 | Thompson | Nov 2003 | B2 |
6654640 | Lyden | Nov 2003 | B2 |
6658294 | Zadeh et al. | Dec 2003 | B1 |
6662053 | Borkan | Dec 2003 | B2 |
6671552 | Merritt et al. | Dec 2003 | B2 |
6671556 | Osorio et al. | Dec 2003 | B2 |
6687538 | Hrdlicka et al. | Feb 2004 | B1 |
6721600 | Jorgenson et al. | Apr 2004 | B2 |
6745077 | Griffith et al. | Jun 2004 | B1 |
6748273 | Obel et al. | Jun 2004 | B1 |
6760624 | Anderson et al. | Jul 2004 | B2 |
6760625 | Kroll | Jul 2004 | B1 |
6804557 | Kroll | Oct 2004 | B1 |
6820019 | Kelly et al. | Nov 2004 | B1 |
6901293 | Rogers et al. | May 2005 | B2 |
6940255 | Loch | Sep 2005 | B2 |
7142923 | North et al. | Nov 2006 | B2 |
7254444 | Moore et al. | Aug 2007 | B2 |
7751891 | Armstrong et al. | Jul 2010 | B2 |
7904161 | Osypka | Mar 2011 | B2 |
20020013613 | Haller et al. | Jan 2002 | A1 |
20030065366 | Merritt et al. | Apr 2003 | A1 |
20040039424 | Merritt et al. | Feb 2004 | A1 |
20060025829 | Armstrong et al. | Feb 2006 | A1 |
20070150019 | Youker | Jun 2007 | A1 |
20070179548 | Armstrong et al. | Aug 2007 | A1 |
20070216366 | Inamine | Sep 2007 | A1 |
20080097544 | Gandhi et al. | Apr 2008 | A1 |
20120197341 | Cowley et al. | Aug 2012 | A1 |
Number | Date | Country |
---|---|---|
0108749 | Feb 2001 | WO |
2004075982 | Sep 2004 | WO |
Entry |
---|
International Patent Application No. PCT/US2011/061003, International Search Report and Written Opinion dated Jun. 28, 2012, 10 pages. |
Terry, R.S., et al., “The Implantable Neurocybernetic Prosthesis System,” Pacing and Clinical Electrophysiology, vol. 14, No. 1, (Jan. 1991), pp. 86-93. |
Woodbury, J.W. et al., “Vagal Stimulation Reduces the Severity of Maximal Electroshock Seizures in Intact Rats: Use of Cuff Electrode for Stimulating and Recording,” PACE, vol. 14, (Jan. 1991), pp. 94-107. |
International Application No. PCT/US2007/000337, Written Opinion dated Jul. 27, 2008, 8 pgs. |
International Application No. PCT/US2005/026514, Written Opinion dated Oct. 10, 2006, 4 pgs. |
Number | Date | Country | |
---|---|---|---|
20120277832 A1 | Nov 2012 | US |